Abstract
Mantle cell lymphoma, despite its common derivation from a t(11;14) error that occurs in a naïve B-cell leading to overexpression of cyclin D1 protein, is characterized by substantial heterogeneity in biology and clinical outcome. Unlike other non-Hodgkin lymphoma types, it is more common in men. Clinical presentation patterns vary from nodal to splenomegaly with leukemia to gastrointestinal involvement. Biological variability is linked to tumor cell proliferation. Increased monocyte/macrophages and their associated proinflammatory cytokines are associated with inferior outcomes. These clues mandate that new treatments should target signal pathways that contribute to these adverse outcomes.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 825-835 |
| Number of pages | 11 |
| Journal | Hematology/Oncology Clinics of North America |
| Volume | 34 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 2020 |
Keywords
- Cell proliferation
- Cytokines
- Metabolomics
- Minimal residual disease
- TP53 mutation
ASJC Scopus subject areas
- Hematology
- Oncology